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Abstract
Background: Liver failure in experimental animals or in human cirrhosis elicits neuroinflammation. Prolyl oligopeptidase
(PREP) has been implicated in neuroinflammatory events in neurodegenerative diseases: PREP protein levels are
increased in brain glial cells upon neuroinflammatory insults, but the circulating PREP activity levels are decreased
in multiple sclerosis patients in a process probably mediated by bioactive peptides. In this work, we studied the
variation of PREP levels upon liver failure and correlated it with several inflammatory markers to conclude on the
relation of PREP with systemic and/or neuroinflammation.
Methods: PREP enzymatic activity and protein levels measured with immunological techniques were determined
in the brain and plasma of rats with portacaval shunt (PCS) and after treatment with ibuprofen. Those results were
compared with the levels of PREP measured in plasma from cirrhotic patients with or without minimal hepatic
encephalopathy (MHE). Levels of several pro-inflammatory cytokines and those of NO/cGMP homeostasis metabolites
were measured in PCS rats and cirrhotic patients to conclude on the role of PREP in inflammation.
Results: In PCA rats, we found that PREP levels are significantly increased in the hippocampus, striatum and cerebellum,
that in the cerebellum the PREP increase was significantly found in the extracellular space and that the levels
were restored to those measured in control rats after administration of an anti-inflammatory agent, ibuprofen. In
cirrhotic patients, circulatory PREP activity was found to correlate to systemic and neuroinflammatory markers
and had a negative correlation with the severity of the disease, although no clear relation to MHE.
Conclusions: These results support the idea that PREP levels could be used as indicators of cirrhosis severity in
humans, and using other markers, it might contribute to assessing the level of neuroinflammation in those patients.
This work reports, for the first time, that PREP is secreted to the extracellular space in the cerebellum most probably
due to glial activation and supports the role of the peptidase in the inflammatory response.
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Background
Hepatic encephalopathy (HE) is a complex neuropsychi-
atric syndrome resulting from chronic or acute liver dis-
ease; 30–50 % of patients with liver cirrhosis present
minimal forms of HE [1]. Minimal HE (MHE) is the first
stage in the spectrum of HE [2, 3], and it is usually diag-
nosed using the psychometric HE test [4]. Two main
factors contribute to the neurological alterations in HE:
hyperammonemia and inflammation [5–7]. In patients
with minimal HE, cognitive impairment correlates with
serum levels of inflammatory cytokines IL-6 and IL-18
[8]. We have shown that neuroinflammation is produced
upon mimicking liver failure in rats [5, 6], which models
human HE. Furthermore, anti-inflammatory drugs as
ibuprofen [5] or MAPK-p38 inhibitors [9] have shown to
restore cognitive function in PCS rats.
Prolyl oligopeptidase (PREP; EC 3.4.21.26) is a serine
peptidase able to cleave short peptides (<30 amino acids)
at the C-side of a proline residue [10, 11]. Although
present in all organs, PREP is localized in specific cells
and cell layers across the brain and peripheral tissues [12].
In the mature healthy brain, PREP is highly expressed in a
certain group of neurons in well-defined areas such as the
striatum, cortex, hippocampus and cerebellum but
scarcely detectable in glial cells [13, 14]. PREP has been
associated to neurodegeneration [10, 11], proliferation
[15], neuronal differentiation [16], development [17, 18]
and also to inflammation [19–21]. PREP levels have been
found altered in Alzheimer’s (AD), Parkinson’s (PD) [22]
and Huntington’s (HD) diseases (reviewed in [10]). In ex-
periments on PREP overexpressed neuroblastoma cells,
the data suggest that PREP has a role on secretion and
clearance of α-synuclein deposits [23, 24]. Recent data also
indicate that PREP is involved in hormonal regulation
[25–27]. It has been shown that upon an inflammatory in-
sult PREP expression is dramatically increased in astro-
cytes and microglia in the mouse brain [20]. Increased
activated glia in AD and PD has been also related to PREP
expression increase [22]. Previous studies demonstrate
that under specific stimulus activated microglia can
express and secrete PREP, which, in vitro, is toxic for neu-
rons, effect that is partially prevented by specific inhibitors
of PREP [28].
Results so far suggest that the function of PREP is dif-
ferent in different cell types and depends on the peptid-
ase location: intercellular or extracellular [24]. Emerging
evidence suggests that PREP participates in the inflam-
matory response through the modulation of active pep-
tides [19, 21].
Although active research on PREP has been carried out
recently, there is still lack of information on the specific
physiological and pathological mechanisms where this pep-
tidase is involved. Different reports indicate an involve-
ment of PREP in several inflammatory diseases such as
chronic obstructive pulmonary disease [29, 30], lupus ery-
thematosus [31, 32], rheumatoid arthritis [33–35] and
bronchiolitis obliterans syndrome [36] among others [20].
Recently, it has been reported that circulating PREP activ-
ity is significantly decreased in patients of multiple sclerosis
(MS) [19, 37]. Although that the mechanistic link between
PREP and MS has not been defined, it seems that it is re-
lated to inflammation in a complex fashion, where α-2-
macroglobulin, fibrinogen and thymosin β-4 might have a
role [19]. Furthermore, in experimental autoimmune en-
cephalomyelitis (EAE), a mice model of MS, we observed
that animals become more sensitive to the autoimmune
challenge when they are administrated with PREP inhibi-
tors, compared with vehicle-treated EAE mice [19].
In this work, we hypothesized a decreased of circulat-
ing levels of PREP in cirrhosis and wanted to find out if
the relationship was linked to systemic inflammation or/
and neuroinflammation, as judged by the development
of HE. We also intended to find additional information
on the possible role of PREP as a biomarker of (neuro)
inflammation. Additionally, if there were PREP changes
in cirrhosis and/or HE, we also wanted to find out if
those were correlated to changes in inflammatory
markers, like IL-6, IL-8, cGMP, atrial natriuretic peptide
and nitrates/nitrites, in order to find a possible mechan-
istic link between the pathological states.
Methods
HE rat model of portacaval shunt (PSC)
Male Wistar rats were subjected to portacaval anastomosis
as described by Lee and Fisher [38]. Control rats were
sham operated. The experiments were approved by the
ethical committee of the Centro de Investigación Principe
Felipe complying with the European Community guide-
lines for experimental animal care and management.
In vivo microdialysis
Rats were anesthetized with isoflurane, and a microdialy-
sis cannula (CMA, Stockholm, Sweden) was implanted
in the cerebellum (AP −10.2, ML −1.6 and DV −1.2), as
described in [39]. After 48 h, a microdialysis probe
(CMA/12; 3 mm long) was implanted in the freely mov-
ing rat and perfused (3 μl/min) with artificial cerebro-
spinal fluid (in mM): NaCl, 145; KCl, 3.0; CaCl2, 2.26;
buffered at pH 7.4 with 2 mM phosphate. After a 2–3-h
stabilization period, samples were collected every 30 min
for 6 h. PREP activity was measured in samples as de-
scribed below. Activity was determined by triplicate for
each time point (see figure caption).
Immunohistochemistry
PREP density was determined in xylene dewaxed brain
sections, rehydrated with graded alcohols and washed
with 0.1 M phosphate-buffered saline (PBS). The antigen
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retrieval was processed in a microwave oven in citrate
buffer (pH 6.0) for 3 × 5 min. Endogenous peroxidase ac-
tivity was inactivated with 5 % hydrogen peroxidase for
5 min and non-specific binding was blocked with 10 %
Normal Rabbit Serum (Product# S-5000; Vector Labora-
tories) in PBS. Primary antibody (1:500, affinity purified
chicken IgY, [14, 20, 40]) was added and incubated over-
night at +4 °C in moist chambers. After two PBS washes,
the sections were incubated with the secondary antibody
(1:1000, rabbit anti-chicken FITC, #31501, Pierce Bio-
technology, or 1:1000 anti-goat horseradish peroxidase
complex, Santa Cruz Biotechnology Inc., Dallas, TX,
USA) for 2 h. Double immunofluorescence with PREP
antibody was performed after PBS washes. Vectashield
(Product # H-1000, Vector Laboratories) or Vectashield
with DAPI (Product # H-1200, Vector Laboratories) was
used as mounting medium and to visualize the cell nuclei.
Density was determined in digitalised images in at least
three randomly selected fields per tissue on PCA or con-
trol sections, from 4 to 9 animals (see figure captions).
For PREP cellular localization experiments by confocal
microscopy, brains were dissected out and postfixed in
the same fixative and, subsequently, transferred to phos-
phate buffer (PB) with 0.1 sodium azide. Coronal sec-
tions (30 μm) were cut on a vibratome (Leica VT 1000S)
and were stored at 4 °C in PB with 0.1 % azide until fur-
ther processing. Free-floating sections were washed and
sequential incubations with blocking serum and primary
antibodies (overnight 4 °C) were performed. Brain sec-
tions were stained with anti-PREP (1:300, Abcam, UK),
anti-GFAP (1:400, Sigma-Aldrich, USA) and anti-NeuN
(1:100, Merck-Millipore, Germany). Finally, the second-
ary antibodies Alexa fluor 488 Donkey anti-mouse,
Alexa fluor 555 Donkey anti-goat and Alexa fluor 647
Donkey anti-rabbit (all of them, 1:400, Invitrogen, USA)
were incubated for 1 h at room temperature. To assess
the co-expression of PREP with astrocytes, we analysed
the double immunofluorescence stained sections with a
confocal microscope. In the co-localization studies, sec-
tions were studied with a spectral confocal microscope
(Leica TCS-SP2-AOBS) at ×63 with an oil-immersion ob-
jective and imaging software (Leica Confocal Software Lite
Version). All analyses were carried out in sequential scan-
ning mode (lasers 488 Ar, 561 DPSS and 633 He/Ne) to
eliminate the possibility of cross-bleeding between chan-
nels. Results were obtained from projections in the z-axis.
Prolyl oligopeptidase enzymatic activity
Serum or microdialysate samples (50 μl) were used to
assay PREP activity by measuring the fluorescence re-
leased from the substrate N-carbobenzoxy-glycyl-prolyl-
7-amido-4-methyl-coumarin (Z-Gly-Pro-AMC, 200 μM),
as previously reported [17], and in the absence or
presence of 50 nM KYP-2047. The activity sensitive to
the inhibitor is reported as PREP activity.
Western blotting
Rat tissues were homogenized in 50 mM phosphate buf-
fer pH = 7 (5 volumes), and further disrupted by sonic-
ation (2 × 5 s). After a low-speed centrifugation
(1000×g), samples obtained this way, or human/rat
plasma samples (for preparation see below), were diluted
1:1 with loading buffer (100 mm Tris/HCl, pH 6.8, 70 %
glycerol, 2 % SDS, 0.005 % bromophenol blue, 10 mM
mercaptoethanol) and separated on 10 % polyacryl-
amide/bis-acrylamide Tris/HCl discontinuous gels. Gels
were transferred to nitrocellulose for blotting. Western
blot was performed under standard conditions using af-
finity purified chicken anti-PREP IgY [40], diluted 1:500
with 0.5 m NaCl, 20 mm Tris–HCl pH 7.5, 5 % skim
milk and 0.05 % Tween 20 (TTBS) overnight. After that,
first antibody was washed three times with TTBS and in-
cubated 1 h with anti-chicken horseradish peroxidase
complex (Santa Cruz Biotechnology Inc., Dallas, TX,
USA) diluted 1:3000 in TTBS. After washing, protein
visualization was performed using a chemoluminescent
substrate kit (Pierce, Rockford, IL, USA), following the
manufacturer’s instructions. Western blot images were
analysed, and the optical density (OD) values of protein
bands were determined by using QuantityOne-software
(version 4.6.9, Bio-Rad).
Ibuprofen treatment of PCS rats
Treatment with ibuprofen was performed as performed
in Cauli et al. [39]. Rats subjected to portacaval anasto-
mosis, and also those sham operated, were treated daily
with S-(1) Ibuprofen (Fluka, Seelze, Germany). The
treatment with ibuprofen started 10 days after PCS sur-
gery, or sham operation. Ibuprofen dissolved in sterile
saline was injected intraperitoneally. Rats received 0, 5,
15 or 30 mg/kg ibuprofen per day in 0.5 ml/100 g body
weight. Rats were sacrificed after 5 weeks of treatment.
Patients with liver cirrhosis and controls
Forty patients with diagnosed liver cirrhosis after histo-
logical study, and 20 healthy controls without no clinical,
analytical, serologic and ecographic evidence of liver
malfunction, were enrolled in the study after informed
consent. After performing the psychometric tests, pa-
tients were divided into those diagnosed with or without
MHE (see below). The composition of the groups, the
number of subjects, age, sex and aetiology of the liver
disease are given in Table 1.
The study protocol complied with the ethical guidelines
of the Declaration of Helsinki of 1975 and was approved
by the Scientific and Ethical Committees of the Hospital.
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Diagnosis of minimal hepatic encephalopathy
MHE was diagnosed using the Psychometric Hepatic
Encephalopathy Score (PHES), recommended as the
“gold standard” [4, 32]. PHES comprises five psychomet-
ric tests: digit symbol test (DST), number connection
test A (NCT-A), number connection test B (NCT-B),
serial dotting test (SD) and the line tracing test (LDT).
The score in each test and the PHES were calculated
adjusting for age and education level by means of Spanish
normality tables (www.redeh.org). Patients were classified
as having MHE when the score was less than −4 points [8].
Collection of plasma and serum
Blood (5 ml) was taken in BD Vacutainer tubes with or
without EDTA (for plasma and serum, respectively) and
centrifuged at 500×g for 10 min. The supernatant was col-
lected and stored frozen at −80 °C in aliquots of 500 μl.
Determination of nitrates + nitrites
Nitrate (NO3
−) was measured in plasma as nitrite after
enzymatic conversion by nitrate reductase as previously
described [6, 39].
Determination of ammonia
Ammonia content in human blood was measured as
described previously [5]. By duplicate, aliquots of blood
(150 μl) were added to 150 μl of ice-cold 10 %
trichloroacetic acid. After centrifugation at 12,000×g
for 10 min at 4 °C, the supernatant was collected and
neutralized with 15 μl of KHCO3 to pH 7. In duplicates,
50-μl samples were mixed with 32.5 μl of the reaction
mixture (phosphate buffer 0.2 M, pH 8; α-ketoglutarate
0.6 M pH 7; NADH 10 mM) and added 10 μl of glutamate
dehydrogenase. Ammonia was measured with a micro-
plate fluorimeter (Fluoroskan Ascent, Thermoscientific)
using excitation and emission filters of 355 and 460 nm,
respectively. Ammonia from PCA rats was measured
using the kit II Ammonia Arkray test (PocketChem BA,
Arkray) according the kit protocol, using 20 μL of
blood.
Isolation of lymphocytes and activation of soluble
guanylate cyclase by the NO-generating agent S-nitroso-
N-acetylpenicillamine (SNAP) in intact lymphocytes
Lymphocytes were obtained as previously described
[40, 41] and resuspended in 800 μl Locke’s solution
without magnesium (in mM: NaCl, 154; KCl, 5.6;
NaHCO3, 3.6; CaCl2, 2.3; glucose, 5.6; 4(2-hydroxyethyl)-
1-piperazine-ethanosulfonic acid, 5; pH 7.4) containing
0.3 mM 3-isobuthyl-1-methylxantine (IBMX, Sigma,
Germany). Quality of the preparation was assessed by mi-
croscopy, and the viability was determined by trypan blue
assay. Lymphocytes were distributed in 200 μl aliquots
and incubated for 15 min at 37 °C in a water bath before
addition of SNAP (1 mM, Molecular Probes, Eugene, OR,
USA). Incubation was continued for 15 min. Subsequently,
the cells were collected by centrifugation at 450×g for
10 min. The pellet was resuspended in 200 μl of lysis solu-
tion (0.5 % dodecyl-trimethylammonium bromide). Pro-
tein was measured by the BCA™ Protein Assay (Thermo
Scientific, Rockford, IL, USA).
Determination of cGMP in plasma and lymphocytes
The level of cGMP in plasma and in lymphocytes was
determined using the BIOTRAK™ cGMP enzyme im-
munoassay kit from Amersham (GE Healthcare, Life
Sciences, UK).
Determination of interleukins in serum
IL-6 was determined using the BIOTRAK Easy ELISA sys-
tem from Amersham (GE Healthcare, Life Sciences, UK);
IL-18 was measured using an ELISA system from Bender
MedSystems GMbH (Austria). The measurements were
performed with a micro plate reader (Multiskan Ascent,
Thermo Electron Corp.).
Statistical analysis
Values are given as mean ± standard deviation. We used
t test to analyse immunohistochemical or western band
densities, comparing the results with the control values
for every tissue. Enzymatic activity results on serum
samples were analysed by one-way ANOVA followed by
post hoc Bonferroni test. Calculations were performed
using GraphPad PRISM Version 4.0. The probability
level accepted for significance was p < 0.05. Correlation
analysis was performed using the SPSS software, Version
17.0 (SPSS Inc, Chicago, USA), and two-sided p values
<0.05 were considered significant.
Results
PREP changes in the brain of HE rat model
After surgically subjected to portacaval shunt (PCS), rats
develop liver atrophy, hyperammonemia, inflammation
and minimal hepatic encephalopathy similarly to the
situation in patients with liver cirrhosis [5]. Accordingly,
Table 1 Demography of controls and patients
Control Patients without MHE Patients with MHE
Total individuals
(male/female)
20 (8/12) 20 (15/5) 20 (12/8)
Agea (years) 44 ± 11 55 ± 10 65 ± 10
Alcohol – 20 20
Child-Pugh A/B/C – 13/7/0 12/8/0
MELD scorea – 10 ± 3 9.8 ± 3
Ascites – 1 2
MHE minimal hepatic encephalopathy, MELD model end-stage liver disease
amean ± SD
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the brain of PCS rats was analysed for PREP levels by
immunohistochemistry and western blot. Figure 1a
shows PREP immunohistochemistry of different areas of
the PCS rat brain after 6–12 weeks and compared with
the images of the same areas of the brain from sham
rats. There was a significant increase of PREP immuno-
staining in the PCS model. The increase was especially
marked in the CA1 layer of the hippocampus. The increase
ranged from 40 to 100 % depending on the brain area. The
optical density difference for the different areas analysed is
shown in Fig. 1b. To verify these results, we dissected the
cerebellum, cortex, hippocampus and striatum, homoge-
nized them and measured PREP levels by western im-
munoblotting. These results are shown in the Fig. 2. With
the exception of cortex, PREP levels were found increased
significantly in all areas of the brain of PCS rats (Fig. 2).
PCSSham
Hip
Cx
Str
A
B
Hip
Cx
Str
Fig. 1 The expression of PREP in the brain of PCS rats is substantially increased as shown by a immunohistochemistry of sections of the hippocampus
(Hip), frontal cortex (Cx) and striatum (Str), compared with sham operated rat brain. This increase in density was quantitated as represented in (b) (n= 4–5)
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PREP changes in the plasma of HE rats
We measured PREP activity and protein levels in
plasma from PCS rats (Fig. 3). We found a statistically
significant (p = 0.023) reduction of PREP activity in
PCS (6.167 U ± 0.2333, n = 3) compared to sham oper-
ated controls (11.97 ± 1.249, n = 4). In addition, PREP
protein levels in PCS plasma, measured by western
blot, were also found decreased to 52.58 % ±14.63,
compared to sham operated controls (p < 0.05) (Fig. 3b).
This is consistent with the drop in PREP activity. The
decrease on PREP was parallel to an increase level of
ammonia (Fig. 3c). Blood ammonia levels were in-
creased (p < 0.001) in PCS rats (361 ± 39 μM) compared
with sham operated rats (51 ± 13 μM).
PREP co-localizes with neurons and glial cells in the brain
of PCS rats
Cellular localization of PREP in different areas of the PCS
rat brain was investigated by confocal microscopy (Fig. 4).
PREP was clearly positive in neurons, especially in the CA1
layer of the hippocampus (Fig. 4a) and cerebellar Purkinje
cells (Fig. 4h) as described before [13, 14]. However, PREP
was not found only in neurons, as is normally found in
healthy rat brain [13, 14]. In PCS brain, PREP was observed
within hippocampal astrocytes located in the molecular
layer and in the dendritic region of the neurons of the CA1
layer (Fig. 4d) and remarkably in glial cells of the cerebellar
cortex (Fig. 4e) and white matter (Fig. 4g).
Extracellular PREP is increased in the brain of HE model
rats
We have shown that hyperammonemic and portacaval
shunt models of HE in rats develop neuroinflammation in
specific areas of the brain, especially in cerebellum [6, 40].
As PREP was increased in the brain of PCS rats, we
wanted to test if the peptidase was also being secreted
from the cells where this was up-regulated. Accordingly,
we collected extracellular fluid from the cerebellum of
PCS rats by microdialysis. We found that the amount of
extracellular PREP is dramatically increased in PCS rats,
compared with the sham operated controls as shown in
Fig. 5. The activity detected in sham operated rats was just
above the limit of detection (0.012 ± 0.02033 U, N = 5),
while in PCS rats, PREP activity levels were increased al-
most 20 times (0.1845 ± 0.05668 U, N = 4).
PREP levels are restored to normal upon ibuprofen
treatment of PCS rats
We have reported that treatment with an anti-
inflammatory agent, ibuprofen, restores motor function in
PCS rats and normalizes glutamate in substantia nigra
pars reticulata (SNr) [39]. PCS rats, and sham operated,
were treated with 0, 5, 15 and 30 mg/kg of ibuprofen for
5 days. Figure 6 shows the levels of PREP activity and pro-
tein in striatum of these treated rats. It is observed that
striatal PREP is increased in PSC untreated rats compared
with sham untreated animals, as shown in Figs. 1 and 2,
but a gradual decrease of the levels to control values is
achieved as the ibuprofen dose is increased.
PREP activity is reduced in cirrhotic patients regardless of
HE, but PREP protein was found reduced only in patients
with MHE
We measured the activity of PREP in plasma from patients
with liver cirrhosis, which presented the absence (n = 20) or
presence (n = 20) of the symptoms of MHE and compared
with the measurements from healthy volunteers (n = 20).
PREP activity was found significantly decreased in plasma
from all cirrhotic patients (Fig. 7a). Relative to control, cir-
rhotic patients showed a decrease of 65 % (patients without
MHE, P < 0.001) and 50 % (patients with MHE, p < 0.001).
However, the difference between patients with or without
MHE was not significant.
On the other hand, when the PREP protein levels were
measured by western blot (Fig. 7b), no change was ob-
served in PREP protein in cirrhotic patients without
MHE, but it was found somehow reduced in patients
presenting MHE.
PREP activity correlates with IL-6, IL-18 and GMPc levels
in cirrhosis
It is known that systemic inflammation, upon liver failure,
contributes to encephalopathy in cirrhosis, in a process
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Fig. 2 PREP expression was also detected increased by western blotting
in the brain of PCS rats, compared with sham operated control rats (line
at 100 %), especially in the cerebellum (Cb, n= 9), hippocampus (Hip,
n= 6) and striatum (Str, n= 4). The increase was not significant in the
cortex (Cx, n= 4)
Tenorio-Laranga et al. Journal of Neuroinflammation  (2015) 12:183 Page 6 of 14
SHAM PCS SHAM PCS
PREP
SHAM PCS
0.0
2.5
5.0
7.5
10.0
12.5
*
P
R
E
P
 a
ct
iv
ity
 (U
)
SHAM PCS
0
20
40
60
80
100
*
C
on
te
nt
 o
f P
R
E
P
(%
 o
f S
ha
m
)
A
m
m
on
ia
  (
M
)
SHAM PCS
0
100
200
300
400
500
***
A B C
µ
Fig. 3 PREP activity (a) and protein levels in plasma, determined by western blotting (b), are decreased (p < 0.05) in PCA rats (black bar, n = 4)
compared with sham operated control rats (white bar, n = 5). Representative blots are show in the lower panel. c, ammonia levels in PCA are
increased relative to control
Fig. 4 PREP is expressed in neurons and astrocytes in hippocampus and cerebellum of PCS rats. PREP (red) is expressed mainly in the neurons of
the CA1 region of the hippocampus visualized with NeuN (green) (a). High magnification images showed co-localization (arrows) of PREP (red)
with astrocytes stained with glial fibrillary acidic protein (GFAP; green) in the hippocampus (b–d), in the white matter of the cerebellum (e–g)
and the cerebellar cortex (h–j). To note is the strong PREP expression in Purkinje cells (arrow heads in (h, j)) also co-localization with the glia
Bergman (arrows). Nuclear marker: DAPI (cyan). Scale bar: b–g 10 μm; a, h–j 30 μm
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that is characterized by microglial activation with the
increase of cytokines and activation of GMPc-pathways
[42–44]. Several of those parameters, and others that
are commonly measured in clinical samples over diag-
nosis of cirrhosis and/or MHE, were assayed in the pa-
tient cohort in this study to confirm the assessment of
diagnosis and to correlate them with those values of
PREP activity found modified. The results are shown in
Table 2 along with the PHES. The changes found in ni-
trates, plasma cGMP, basal cGMP in lymphocytes and
SNAP-induced cGMP increase, as well as IL-6, IL-18
and ammonia, were consistent with described changes
in cirrhosis. Creatinine, bilirubin, albumin and INR are
clinical parameters frequently utilized in cirrhotic pa-
tients to estimate MELD and Child-Pugh. We observed
that we confirmed that bilirubin and albumin were sig-
nificantly modified in cirrhotic patients. It was also ob-
served that the changes in cGMP, IL-6 and IL-18
correlated with MHE. When we compared the parame-
ters measured with the changes found in the levels of
PREP, we found that the changes in IL-6, IL-18, both
plasma and lymphocyte basal cGMP and SNAP-induced
cGMP, as well as total bilirubin and albumin, correlated
with PREP changes (Table 3). To evaluate if the changes
in peptidase levels correlated with the severity of the
pathologic state of the patients, we compared those re-
sults with the scores obtained by Child-Pugh or the
model end-stage liver disease (MELD). We did observe
a strong correlation between Child-Pugh and MELD
scores and the PREP levels (Table 3). In further analysis,
no correlation was found between PREP activity and
performance in different coordination and attention
tests, such as Stroop, map search or bimanual coordin-
ation test (not shown).
Discussion
Recently, PREP has been proposed as a modulator of the
inflammatory response in different pathologies of the lung
[29, 30, 45–49]. This response involves a multistep process
resulting in the formation of the chemoattractant peptide,
N-acetylated-proline-glycine-proline (Ac-PGP) a biomarker
for chronic obstructive pulmonary disease (COPD) [29].
Furthermore, it has been shown that PREP is involved in
the generation of N-acetyl-seryl-aspartyl-lysyl-proline (Ac-
SDKP) form thymosin-β10 in the kidney [50, 51] and that
these peptide levels decrease in renal fibrosis and in-
flammatory cell infiltration in hypertensive rats [52].
Moreover, PREP has been reported overexpressed in in-
flammatory cells in culture [28] and in brain glial cells
upon neuroinflammatory insults [20]. On the other
hand, plasma PREP has been reported particularly re-
duced in patients with relapsing remitting and primary
progressive-multiple sclerosis, pathologies with a prom-
inent inflammatory component [19, 37]. In this paper,
we measured inflammatory markers in cirrhotic patients
and correlated the circulating levels of PREP in search
for a relation to neuroinflammation developed in MHE
and compare these correlations with PREP expression
in a model of MHE in rats.
We found that circulating PREP activity was substantially
reduced in all cirrhotic patients but those changes did not
have evident correlation to MHE. However, when assaying
PREP protein by western blot, a decrease was only found
in patients with MHE. It is important to note, that it has
been established that PREP activity levels do not necessary
correspond to protein levels and that PREP has also non-
catalytic functions [12, 13, 16, 24]. Thus, PREP activity
levels detected in plasma are the result not only of the
levels of protein but also of the levels of activity modula-
tors, like reactive oxygen species, α-2-macroglobulin and
other peptides [19]. We have recently shown that cirrhotic
patients, with or without MHE, show increased oxidative
stress in blood compared with control subjects, as reflected
by an increased lipid peroxidation, DNA oxidation, protein
carbonylation, high 3-nitrotyrosine level and higher oxi-
dized/reduced glutathione ratio [53]. It is therefore likely
that increased oxidative stress may contribute to reduced
PREP activity in cirrhotic patients.
On the other hand, it has been described that MHE
correlates with increased levels of the pro-inflammatory
cytokines IL-6 and IL-18 and with altered nitric oxide
(NO)-cGMP homeostasis and increased activation of
soluble guanylate cyclase by NO in freshly isolated lym-
phocytes [8, 40]. Specially, increased levels of serum IL-6
and IL-18 correlated with cognitive impairment in patients
with cirrhosis of the liver and minimal hepatic encephal-
opathy [8]. We found significant differences in the levels
of plasma cGMP, IL-6, and IL-18, between patients with-
out MHE relative to those who presented MHE (Table 2).
Fig. 5 Brain extracellular PREP activity measured in the dialysate of
cerebellum microdialysis of sham operated control rats (white bar)
and PCS rats (black bar) (n = 4)
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In further correlations, we found that these particular pa-
rameters, plasma cGMP, IL-6 and IL-18, did significantly
correlate with PREP activity. In addition, parameters like
lymphocyte basal cGMP, SNAP-induced cGMP, bilirubin
and albumin, that are markers of cirrhosis in general, and
some of them are parameters to assay disease severity, re-
markably also correlated with the general PREP decrease
in cirrhosis (Table 3). Inversely, levels of ammonia, as ex-
pected, were significantly increased in cirrhosis, but they
did not correlate with the changes in PREP. This, and the
correlations found with plasma cGMP and IL’s, might be
an indication that PREP control is mechanistically con-
nected to the changes caused by increased in ammonia,
rather than with increase of ammonia itself. It is interesting
to note that we found here a negative correlation between
PREP activity and the severity of cirrhosis, as Child-Pugh
and MELD scores. Child-Pugh assigns a score from 1 to 3
reflecting the severity of ascites, hepatic encephalopathy,
international normalized ratio (INR) of prothrombin time,
albumin and bilirubin. On the other hand, the scale for
MELD system is wider (from 0 to 50) and based on serum
bilirubin, serum creatinine and prothrombin time,
which are more objective variables in estimating mortal-
ity in patients with the chronic disease [54]. We found
here that circulating levels of total bilirubin, and also
those of albumin, correlated also with the changes in
PREP activity (Table 3). In general, the greater the score in
both Child-Pugh and MELD systems, the greater the
Fig. 6 PREP increased in PCA rats is recovered to control level after ibuprofen treatment. Groups of 4–5 animals of control sham operated rats
(left) and PCA rats (left), were administrated with 0, 5, 15 and 30 mg/kg for 4 days, and striatal PREP levels of activity (upper graph) and protein
(lower graph) were measured in both groups. The shade of grey in the bars increases with the increase on ibuprofen dose as showed. Statistical
p values between selected bars are shown
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severity of the liver disease, and the lower the circulating
PREP activity level, according to our results. However, this
observation has to be taken with some caution, since our
study did not include cirrhosis patients with a Child-Pugh
C score, mainly because of the complex clinics of the dis-
ease at this stage.
Animal models of HE have been established and charac-
terized. Upon portacaval shunt (PCS), or hyperammonemia
(HA), conditions that mimic liver failure, rats develop en-
cephalopathy [5, 6, 55, 56]. In this work, we found that
PREP immunoreactivity was increased in the hippocampus,
cortex and cerebellum in the PCS model. The PREP in-
crease was also confirmed by western blotting for the
cerebellum, striatum and hippocampus. In addition, we re-
corded an increase of PREP localized in astrocytes in the
hippocampus and cerebellum. Conversely, but in parallel
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Fig. 7 a Average PREP activity in cirrhotic patients without (triangles) or with (inverted triangles) symptoms of MHE was significantly decreased compared
with healthy subjects (***p < 0.001). b The levels of PREP protein in patients without MHE (black bar) showed no significant change, but these levels are
apparently reduced in patients with MHE (hatch pattern bar), in comparison with PREP levels in control healthy subjects (white bar). A representative
western blot is shown in c
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with the results found in cirrhotic patients, we also
detected a decrease in circulating PREP in PCS rats. The
alterations in circulating levels of PREP in PCS rats, mea-
sured enzymatically and by western, are in parallel with
those found in cirrhotic patients with MHE; the activity of
PREP is reduced in plasma of cirrhotic patients with or
without MHE, but the amount of protein is only lower in
plasma of cirrhotic patients with MHE, with respect to the
control, as well this is reduced in PCS rats. This supports
that PCS rats are a good model reproducing the alter-
ations in PREP found in patients with MHE.
Additionally, we measured extracellular PREP in the
cerebellum in PCS rats and found that its activity is sub-
stantially increased. To our knowledge, this is the first
time extracellular PREP has been detected in vivo in the
brain. These results may indicate that concomitant to
central inflammation there is an up-regulation of PREP
in the brain and this might be translocated to the extra-
cellular space, at least in the cerebellum. The strong
increase in the extracellular PREP activity in rats with
HE that we observed may have important consequences
in the modulation of neurotransmission. In fact, the
finding that ibuprofen restores PREP levels to normal in
PCS rats, further supports PREP involvement in the in-
flammatory processes. Several neuropeptides which have
roles in neuroinflammation are substrates of PREP, such
as neurotensin, substance P, TRH and neuropeptide Y,
among others [11]. The increase in extracellular PREP ac-
tivity in HE may lead to enhanced degradation of these
substrates, reducing their extracellular levels, at least in
cerebellum. This could result in altered neurotransmission
which, in turn, would contribute to the cognitive and
motor alterations found in rats with HE. It is important to
note that there have been relatively large number of stud-
ies measuring changes in neuropeptides in response to
PREP inhibition and there has not been consensus on a
true correlation of PREP activity and peptide levels (data
reviewed in [10, 11, 20]). These divergences might be due
Table 2 Values of parameters in the different groups of patients with liver disease and in controls
Parameter Controls Patients without
MHE (p vs. control)
Patients with
MHE (p vs. control)
p values (without
MHE vs. with MHE)
Global ANOVA
p values
PHES −0.2 ± 0.8a −0.4 ± 0.8 −6 ± 2 <0.001 <0.0001
p < 0.001
Nitrates + Nitrites (μM) 18 ± 3 24 ± 8 29 ± 8 ns <0.0001
p < 0.05 p < 0.001
cGMP in Plasma (pmoles/ml) 4 ± 1 7 ± 3 10 ± 4 <0.05 <0.0001
p < 0.05 p < 0.001
Lymphocyte basal cGMP (pmol/mg prot) 0.169 ± 0.06 0.078 ± 0.06 0.047 ± 0.02 ns <0.0001
p < 0.001 p < 0.01
SNAP-induced cGMP increase (fold) 11 ± 3 21 ± 9 22 ± 11 ns 0.0004
p < 0.01 p < 0.01
ANP (ng/ml) 0.014 ± 0.003 0.015 ± 0.002 0.015 ± 0.002 ns ns
IL-6 (pg/ml) 1 ± 0.6 2.5 ± 1.5 4.7 ± 2.1 <0.001 <0.0001
p < 0.05 p < 0.001
IL-18 (pg/ml) 174 ± 80 281 ± 138 388 ± 138 <0.05 <0.0001
p < 0.05 p < 0.001
Creatinine (mg/dl) 0.74 ± 0.12 0.77 ± 0.19 0.86 ± 0.45 ns ns
Total bilirubin (mg/dl) 0.61 ± 0.16 1.42 ± 0.94 1.05 ± 0.83 ns 0.005
p = 0.003
Albumin (g/dl) 4.49 ± 0.14 3.90 ± 0.56 3.70 ± 0.59 ns <0.001
p = 0.001 p < 0.001
INR 1.06 ± 0.05 1.22 ± 0.36 1.18 ± 0.17 ns 0.08
Ammonia (μM) 72 ± 22 127 ± 40 131 ± 35 ns <0.001
p < 0.001 p < 0.001
Differences between groups were assessed with ANOVA plus post hoc Tukey test
MHE minimal hepatic encephalopathy, PHES Psychometric Hepatic Encephalopathy Score, ANP atrial natriuretic peptide, IL-6 interleukin-6, IL-18 interleukin-18
aValues are expressed as the mean ± SD
Tenorio-Laranga et al. Journal of Neuroinflammation  (2015) 12:183 Page 11 of 14
to the fact that experimental paradigms tested have not
considered the inflammatory factors or glial activation. In
fact, the lack of correlation between neuropeptide levels
and PREP activity in several experiments has been ex-
plained by the inaccessibility of PREP, putatively located
intracellular, to cleave the neuropeptides, located in the
extracellular milieu [26, 27].
The mechanism by which HE increases extracellular ac-
tivity of PREP remains unknown. A possible explanation
would be that neuroinflammation may result in enhanced
release to the extracellular space of PREP, which could be
released either from neurons or from astrocytes. In nor-
mal rats, PREP is present mainly in neurons [13, 14].
However, we show here that in PCS rats it is also expressed
in glial cells. This suggests that neuroinflammation induces
the expression of PREP in glial cells and its release to the
extracellular fluid. This would be in agreement with previ-
ous studies showing that activated microglia can express
and secrete PREP [20, 22], which, in vitro, is toxic for neu-
rons [28]. In HE, as mentioned above, the increase in
extracellular PREP may contribute to alter neuronal func-
tion and neurotransmission, contributing to the neuro-
logical alterations in MHE. This is strongly supported by
the fact that ibuprofen treatment of PCS rats restores the
levels of PREP and, as reported before, also restores the
levels of glutamate in SNr and improves the motor per-
formance of the rats [5, 39]. These effects have also been
observed in other models of hepatic encephalopathy as bile
duct ligation as well as in hyperammonemia [5, 6].
Recently, it has been proposed a synergistic contri-
bution of inflammation and hyperammonemia to HE
[7, 8, 42, 57, 58]. On the other hand, changes of PREP
are apparently correlated to systemic and central inflam-
mation. We observed in PCS rats an increase of PREP in
brain areas, but a decrease of circulating PREP activity. Al-
though, and due to the techniques available to detect
PREP, this cannot be measured in the brain of patients, we
assume that PREP increase in brain is also occurring in
cirrhosis. The molecular mechanisms of these changes are
still unaccounted; however, our data and previous studies
indicate that there is a connection with inflammatory sig-
nalling, operating through different routes in the brain
and in circulation. In the brain, the PREP up-regulation
might be part of the integral process of glial activation,
and most probably it is intervening on the modulation of
the extracellular matrix upon inflammation. The informa-
tion is still scarce to reach any conclusion yet for the
changes of PREP in circulation. The circulating levels of
PREP activity are accounted not only by its protein levels
but also by endogenous modulators and oxidative condi-
tions. The relative levels of circulating PREP protein are
very low, around the limits of detection of western blot-
ting technique. Thus, our assay of protein levels with this
technique has to be taken with care. On the other hand,
we have shown before that PREP activity changes might
be due to an increase of an endogenous PREP inhibitor,
α2-macroglobulin (α2M), other circulating peptides not
yet identified, and on reactive oxygen species (ROS), since
PREP is particularly sensitive to oxidative conditions [19].
We have shown that oxidative stress is increased in blood
of cirrhotic patients [53], which may reduce PREP activity.
However, we found no relation of PREP activity to the
levels of α2M or effect of reducing agents, like DTT, on
enzymatic activity in multiple sclerosis samples or in this
study (data not shown).
Table 3 Correlations of the parameters studied with PREP levels
in plasma of cirrhosis and control subjects
Parameter Correlation statistical parameters
PHES r = ns
p = ns
Child-Pugh r = −0.484
p = <0.001
MELD r = −0.377
p = 0.004
Creatinine r = ns
p = ns
Total bilirubin r = −0.281
p = 0.031
Albumin r = 0.362
p = 0.007
INR r = ns
p = ns
IL-6 r = −0.467
p = 0.001
IL-18 r = −0.295
p = 0.039
cGMP plasma r = −0.333
p = 0.019
Lymphocyte basal cGMP r = 0.431
p = 0.003
SNAP-induced cGMP r = −0.413
p = 0.003
Nitrates + nitrites r = ns
p = ns
ANP r = ns
p = ns
Ammonia r = ns
p = ns
rPearson correlation coefficient, PREP prolyl oligopeptidase, FAP fibroblast
associated protein, DTT dithiothreitol, PHES Psychometric Hepatic
Encephalopathy Score, IL-6 interleukin-6, IL-18 interleukin-18, ANP atrial
natriuretic peptide, MELD model end-stage liver disease, ns not significant
Tenorio-Laranga et al. Journal of Neuroinflammation  (2015) 12:183 Page 12 of 14
Conclusions
In this paper, we report that PREP level is increased in the
brain of HE models, and the peptidase is, at least in the
cerebellum, secreted out from the cells. PREP secretion has
only been seen in vitro in T cells [28]. Furthermore, circu-
lating PREP activity was observed substantially depressed
in cirrhosis and in PCS rats with MHE. Low circulating
PREP activity has been observed upon neuroinflammation
in multiple sclerosis [19]. Our findings did not show a clear
correlation of PREP activity decrease in circulation with
HE. However, a relationship might be present, but it is
masked due to the presence of systemic inflammation,
which in turn might be also affecting PREP activity levels.
This idea is supported by the fact that markers of MHE in
cirrhosis correlated with PREP changes. On the other hand,
PREP might indeed be directly related to neuroinflamma-
tion as we observed a restoration of PREP levels upon ad-
ministration of the anti-inflammatory agent ibuprofen to
PSC rats. These results are encouraging and open research
lines to further study PREP and its relation with the
aetiology of inflammatory conditions, aiming in part to de-
termine if PREP might be considered a valuable biomarker
for inflammation.
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